Needham & Company Q2 Review on Obagi Medical Products (OMPI): Solid, Now Focus Shifts to New Growth Initiatives
Go back to Needham & Company Q2 Review on Obagi Medical Products (OMPI): Solid, Now Focus Shifts to New Growth Initiatives| Obagi Medical Products, Inc. (NASDAQ: OMPI) | Delayed: 23.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.98 | 52 Week High | $25.60 | |||
| Open | $23.98 | 52 Week Low | $10.70 | |||
| Day High | $23.98 | P/E | 26.64 | |||
| Day Low | $23.98 | EPS | $0.90 | |||
| Volume | 6,500 | |||||
